Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company focused on B-cell diseases, with news flow centered on its CD20-targeted monoclonal antibody BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS). This news page aggregates company announcements, clinical data updates, financial results, and corporate presentations related to TGTX stock.
Recent press releases highlight preliminary and reported revenue from BRIUMVI, including disclosures that product revenue consists primarily of net product sales of BRIUMVI in the United States and sales to ex-U.S. partners. Investors can follow updates on revenue guidance, operating expense targets, and commentary on how BRIUMVI commercialization influences overall company performance.
TG Therapeutics also issues frequent news about its development programs. These items include progress in the ENHANCE Phase 3b trial evaluating a simplified intravenous dosing schedule for BRIUMVI, the Phase 3 pivotal program for subcutaneous ublituximab, and the Phase 1 trial of azer-cel, an allogeneic CD19 CAR T therapy in autoimmune disease. Additional releases cover long-term ULTIMATE I & II trial data, real-world ENABLE observational study outcomes, and schedules of data presentations at neurology and multiple sclerosis congresses.
Corporate news includes participation in major healthcare and biotechnology investor conferences, rankings such as the Deloitte Technology Fast 500, and announcements of share repurchase authorizations. By following this TGTX news feed, readers can monitor how clinical results, regulatory milestones, commercialization updates, and financial disclosures intersect for TG Therapeutics and its lead therapy BRIUMVI.
TG Therapeutics (NASDAQ: TGTX) announced data presentations scheduled for the ASCO and EHA annual meetings in May and June 2020. The company will present results from three combination trials, highlighting the GENUINE Phase 3 trial's final results that show a PFS benefit for ublituximab in high-risk CLL patients compared to ibrutinib alone. Additionally, long-term results from umbralisib and ibrutinib combinations will be discussed. The presentations emphasize the ongoing development of TGTX's novel therapies targeting B-cell malignancies.
TG Therapeutics, Inc. (NASDAQ: TGTX) reported a net loss of $51.1 million for Q1 2020, up from $35.2 million in Q1 2019. The company is buoyed by positive topline results from its UNITY-CLL Phase 3 trial and a strong cash position of approximately $154.3 million post-ATM facility utilization. Key milestones include the NDA submission for umbralisib in marginal zone lymphoma (MZL) and follicular lymphoma (FL) and the anticipated release of pivotal trial data in 2020. Despite increased R&D costs of $34 million, the company remains optimistic about future cash sufficiency through 2021.
Summary not available.
Summary not available.